Why the study?
Does prenylamine prevent adriamycin-induced cardiotoxicity in experimental models and oncological patients?
Population
Experimental models (mice, rabbits) and oncological patients (n=26 in one clinical trial) receiving adriamycin
Comparison
Prenylamine vs Placebo or no prenylamine
Design
Review
Authors
Loading...
Early data suggest potential benefit; leaves open clinical utility pending rigorous trials.
Does prenylamine prevent adriamycin-induced cardiotoxicity in experimental models and oncological patients?
Prenylamine shows potential in preventing adriamycin-induced cardiotoxicity based on experimental and early clinical findings.
Milei et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: